Global Gastroesophageal Reflux Disease Therapeutics Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
Table of Contents1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gastroesophageal Reflux Disease Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Antacids
1.2.3 H2 Receptor Blockers
1.2.4 Proton Pump Inhibitors (PPIs)
1.2.5 Pro-kinetic Agents
1.2.6 Others
1.3 Market by Application
1.3.1 Global Gastroesophageal Reflux Disease Therapeutics Market Growth Rate by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacy
1.3.3 Drug Stores
1.3.4 General Stores
1.3.5 Supermarkets
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Gastroesophageal Reflux Disease Therapeutics Market Size (2017-2028)
2.2 Gastroesophageal Reflux Disease Therapeutics Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028
2.3 Global Gastroesophageal Reflux Disease Therapeutics Market Size by Region (2017-2022)
2.4 Global Gastroesophageal Reflux Disease Therapeutics Market Size Forecast by Region (2023-2028)
2.5 Global Top Gastroesophageal Reflux Disease Therapeutics Countries Ranking by Market Size
3 Gastroesophageal Reflux Disease Therapeutics Competitive by Company
3.1 Global Gastroesophageal Reflux Disease Therapeutics Revenue by Players
3.1.1 Global Gastroesophageal Reflux Disease Therapeutics Revenue by Players (2017-2022)
3.1.2 Global Gastroesophageal Reflux Disease Therapeutics Market Share by Players (2017-2022)
3.2 Global Gastroesophageal Reflux Disease Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Gastroesophageal Reflux Disease Therapeutics Revenue
3.4 Global Gastroesophageal Reflux Disease Therapeutics Market Concentration Ratio
3.4.1 Global Gastroesophageal Reflux Disease Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gastroesophageal Reflux Disease Therapeutics Revenue in 2021
3.5 Global Gastroesophageal Reflux Disease Therapeutics Key Players Head office and Area Served
3.6 Key Players Gastroesophageal Reflux Disease Therapeutics Product Solution and Service
3.7 Date of Enter into Gastroesophageal Reflux Disease Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Gastroesophageal Reflux Disease Therapeutics Breakdown Data by Type
4.1 Global Gastroesophageal Reflux Disease Therapeutics Historic Revenue by Type (2017-2022)
4.2 Global Gastroesophageal Reflux Disease Therapeutics Forecasted Revenue by Type (2023-2028)
5 Global Gastroesophageal Reflux Disease Therapeutics Breakdown Data by Application
5.1 Global Gastroesophageal Reflux Disease Therapeutics Historic Market Size by Application (2017-2022)
5.2 Global Gastroesophageal Reflux Disease Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Gastroesophageal Reflux Disease Therapeutics Revenue by Company (2020-2022)
6.2 North America Gastroesophageal Reflux Disease Therapeutics Revenue by Type (2017-2028)
6.3 North America Gastroesophageal Reflux Disease Therapeutics Revenue by Application (2017-2028)
6.4 North America Gastroesophageal Reflux Disease Therapeutics Revenue by Country (2017-2028)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe Gastroesophageal Reflux Disease Therapeutics Revenue by Company (2020-2022)
7.2 Europe Gastroesophageal Reflux Disease Therapeutics Revenue by Type (2017-2028)
7.3 Europe Gastroesophageal Reflux Disease Therapeutics Revenue by Application (2017-2028)
7.4 Europe Gastroesophageal Reflux Disease Therapeutics Revenue by Country (2017-2028)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Revenue by Company (2020-2022)
8.2 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Revenue by Type (2017-2028)
8.3 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Revenue by Application (2017-2028)
8.4 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Revenue by Region (2017-2028)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Vietnam
9 Latin America
9.1 Latin America Gastroesophageal Reflux Disease Therapeutics Revenue by Company (2020-2022)
9.2 Latin America Gastroesophageal Reflux Disease Therapeutics Revenue by Type (2017-2028)
9.3 Latin America Gastroesophageal Reflux Disease Therapeutics Revenue by Application (2017-2028)
9.4 Latin America Gastroesophageal Reflux Disease Therapeutics Revenue by Country (2017-2028)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Gastroesophageal Reflux Disease Therapeutics Revenue by Company (2020-2022)
10.2 Middle East and Africa Gastroesophageal Reflux Disease Therapeutics Revenue by Type (2017-2028)
10.3 Middle East and Africa Gastroesophageal Reflux Disease Therapeutics Revenue by Application (2017-2028)
10.4 Middle East and Africa Gastroesophageal Reflux Disease Therapeutics Revenue by Country (2017-2028)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 U.A.E
11 Company Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Gastroesophageal Reflux Disease Therapeutics Products and Services
11.1.4 AstraZeneca Gastroesophageal Reflux Disease Therapeutics Revenue in Gastroesophageal Reflux Disease Therapeutics Business (2017-2022)
11.1.5 AstraZeneca Gastroesophageal Reflux Disease Therapeutics SWOT Analysis
11.1.6 AstraZeneca Recent Developments
11.2 Eisai
11.2.1 Eisai Company Details
11.2.2 Eisai Business Overview
11.2.3 Eisai Gastroesophageal Reflux Disease Therapeutics Products and Services
11.2.4 Eisai Gastroesophageal Reflux Disease Therapeutics Revenue in Gastroesophageal Reflux Disease Therapeutics Business (2017-2022)
11.2.5 Eisai Gastroesophageal Reflux Disease Therapeutics SWOT Analysis
11.2.6 Eisai Recent Developments
11.3 Takeda Pharmaceutical
11.3.1 Takeda Pharmaceutical Company Details
11.3.2 Takeda Pharmaceutical Business Overview
11.3.3 Takeda Pharmaceutical Gastroesophageal Reflux Disease Therapeutics Products and Services
11.3.4 Takeda Pharmaceutical Gastroesophageal Reflux Disease Therapeutics Revenue in Gastroesophageal Reflux Disease Therapeutics Business (2017-2022)
11.3.5 Takeda Pharmaceutical Gastroesophageal Reflux Disease Therapeutics SWOT Analysis
11.3.6 Takeda Pharmaceutical Recent Developments
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Details
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Gastroesophageal Reflux Disease Therapeutics Products and Services
11.4.4 GlaxoSmithKline Gastroesophageal Reflux Disease Therapeutics Revenue in Gastroesophageal Reflux Disease Therapeutics Business (2017-2022)
11.4.5 GlaxoSmithKline Gastroesophageal Reflux Disease Therapeutics SWOT Analysis
11.4.6 GlaxoSmithKline Recent Developments
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Details
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Gastroesophageal Reflux Disease Therapeutics Products and Services
11.5.4 Johnson & Johnson Gastroesophageal Reflux Disease Therapeutics Revenue in Gastroesophageal Reflux Disease Therapeutics Business (2017-2022)
11.5.5 Johnson & Johnson Gastroesophageal Reflux Disease Therapeutics SWOT Analysis
11.5.6 Johnson & Johnson Recent Developments
11.6 Daewoong Pharmaceutical
11.6.1 Daewoong Pharmaceutical Company Details
11.6.2 Daewoong Pharmaceutical Business Overview
11.6.3 Daewoong Pharmaceutical Gastroesophageal Reflux Disease Therapeutics Products and Services
11.6.4 Daewoong Pharmaceutical Gastroesophageal Reflux Disease Therapeutics Revenue in Gastroesophageal Reflux Disease Therapeutics Business (2017-2022)
11.6.5 Daewoong Pharmaceutical Gastroesophageal Reflux Disease Therapeutics SWOT Analysis
11.6.6 Daewoong Pharmaceutical Recent Developments
11.7 Ironwood Pharmaceuticals
11.7.1 Ironwood Pharmaceuticals Company Details
11.7.2 Ironwood Pharmaceuticals Business Overview
11.7.3 Ironwood Pharmaceuticals Gastroesophageal Reflux Disease Therapeutics Products and Services
11.7.4 Ironwood Pharmaceuticals Gastroesophageal Reflux Disease Therapeutics Revenue in Gastroesophageal Reflux Disease Therapeutics Business (2017-2022)
11.7.5 Ironwood Pharmaceuticals Gastroesophageal Reflux Disease Therapeutics SWOT Analysis
11.7.6 Ironwood Pharmaceuticals Recent Developments
12 Gastroesophageal Reflux Disease Therapeutics Market Dynamics
12.1 Gastroesophageal Reflux Disease Therapeutics Market Trends
12.2 Gastroesophageal Reflux Disease Therapeutics Market Drivers
12.3 Gastroesophageal Reflux Disease Therapeutics Market Challenges
12.4 Gastroesophageal Reflux Disease Therapeutics Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
List of TablesTable 1. Global Gastroesophageal Reflux Disease Therapeutics Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Antacids
Table 3. Key Players of H2 Receptor Blockers
Table 4. Key Players of Proton Pump Inhibitors (PPIs)
Table 5. Key Players of Pro-kinetic Agents
Table 6. Key Players of Others
Table 7. Global Gastroesophageal Reflux Disease Therapeutics Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 8. Global Gastroesophageal Reflux Disease Therapeutics Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028
Table 9. Global Gastroesophageal Reflux Disease Therapeutics Revenue by Region (2017-2022) & (US$ Million)
Table 10. Global Gastroesophageal Reflux Disease Therapeutics Revenue Market Share by Region (2017-2022)
Table 11. Global Gastroesophageal Reflux Disease Therapeutics Revenue by Players (2017-2022) & (US$ Million)
Table 12. Global Gastroesophageal Reflux Disease Therapeutics Market Share by Players (2017-2022)
Table 13. Global Top Gastroesophageal Reflux Disease Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastroesophageal Reflux Disease Therapeutics as of 2021)
Table 14. Ranking of Global Top Gastroesophageal Reflux Disease Therapeutics Companies by Revenue (US$ Million) in 2021
Table 15. Global 5 Largest Players Market Share by Gastroesophageal Reflux Disease Therapeutics Revenue (CR5 and HHI) & (2017-2022)
Table 16. Key Players Headquarters and Area Served
Table 17. Key Players Gastroesophageal Reflux Disease Therapeutics Product Solution and Service
Table 18. Date of Key Manufacturers Enter into Gastroesophageal Reflux Disease Therapeutics Market
Table 19. Mergers & Acquisitions, Expansion Plans
Table 20. Global Gastroesophageal Reflux Disease Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 21. Global Gastroesophageal Reflux Disease Therapeutics Revenue Market Share by Type (2017-2022)
Table 22. Global Gastroesophageal Reflux Disease Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 23. Global Gastroesophageal Reflux Disease Therapeutics Revenue Market Share by Type (2023-2028)
Table 24. Global Gastroesophageal Reflux Disease Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 25. Global Gastroesophageal Reflux Disease Therapeutics Revenue Market Share by Application (2017-2022)
Table 26. Global Gastroesophageal Reflux Disease Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 27. Global Gastroesophageal Reflux Disease Therapeutics Revenue Market Share by Application (2023-2028)
Table 28. North America Gastroesophageal Reflux Disease Therapeutics Revenue by Company (2020-2022) & (US$ Million)
Table 29. North America Gastroesophageal Reflux Disease Therapeutics Revenue by Type (2017-2022) & (US$ Million)
Table 30. North America Gastroesophageal Reflux Disease Therapeutics Revenue by Type (2023-2028) & (US$ Million)
Table 31. North America Gastroesophageal Reflux Disease Therapeutics Revenue by Application (2017-2022) & (US$ Million)
Table 32. North America Gastroesophageal Reflux Disease Therapeutics Revenue by Application (2023-2028) & (US$ Million)
Table 33. North America Gastroesophageal Reflux Disease Therapeutics Revenue by Country (2017-2022) & (US$ Million)
Table 34. North America Gastroesophageal Reflux Disease Therapeutics Revenue by Country (2023-2028) & (US$ Million)
Table 35. Europe Gastroesophageal Reflux Disease Therapeutics Revenue by Company (2020-2022) & (US$ Million)
Table 36. Europe Gastroesophageal Reflux Disease Therapeutics Revenue by Type (2017-2022) & (US$ Million)
Table 37. Europe Gastroesophageal Reflux Disease Therapeutics Revenue by Type (2023-2028) & (US$ Million)
Table 38. Europe Gastroesophageal Reflux Disease Therapeutics Revenue by Application (2017-2022) & (US$ Million)
Table 39. Europe Gastroesophageal Reflux Disease Therapeutics Revenue by Application (2023-2028) & (US$ Million)
Table 40. Europe Gastroesophageal Reflux Disease Therapeutics Revenue by Country (2017-2022) & (US$ Million)
Table 41. Europe Gastroesophageal Reflux Disease Therapeutics Revenue by Country (2023-2028) & (US$ Million)
Table 42. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Revenue by Company (2020-2022) & (US$ Million)
Table 43. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Revenue by Type (2017-2022) & (US$ Million)
Table 44. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Revenue by Type (2023-2028) & (US$ Million)
Table 45. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Revenue by Application (2017-2022) & (US$ Million)
Table 46. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Revenue by Application (2023-2028) & (US$ Million)
Table 47. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Revenue by Region (2017-2022) & (US$ Million)
Table 48. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Revenue by Region (2023-2028) & (US$ Million)
Table 49. Latin America Gastroesophageal Reflux Disease Therapeutics Revenue by Company (2020-2022) & (US$ Million)
Table 50. Latin America Gastroesophageal Reflux Disease Therapeutics Revenue by Type (2017-2022) & (US$ Million)
Table 51. Latin America Gastroesophageal Reflux Disease Therapeutics Revenue by Type (2023-2028) & (US$ Million)
Table 52. Latin America Gastroesophageal Reflux Disease Therapeutics Revenue by Application (2017-2022) & (US$ Million)
Table 53. Latin America Gastroesophageal Reflux Disease Therapeutics Revenue by Application (2023-2028) & (US$ Million)
Table 54. Latin America Gastroesophageal Reflux Disease Therapeutics Revenue by Country (2017-2022) & (US$ Million)
Table 55. Latin America Gastroesophageal Reflux Disease Therapeutics Revenue by Country (2023-2028) & (US$ Million)
Table 56. Middle East and Africa Gastroesophageal Reflux Disease Therapeutics Revenue by Company (2020-2022) & (US$ Million)
Table 57. Middle East and Africa Gastroesophageal Reflux Disease Therapeutics Revenue by Type (2017-2022) & (US$ Million)
Table 58. Middle East and Africa Gastroesophageal Reflux Disease Therapeutics Revenue by Type (2023-2028) & (US$ Million)
Table 59. Middle East and Africa Gastroesophageal Reflux Disease Therapeutics Revenue by Application (2017-2022) & (US$ Million)
Table 60. Middle East and Africa Gastroesophageal Reflux Disease Therapeutics Revenue by Application (2023-2028) & (US$ Million)
Table 61. Middle East and Africa Gastroesophageal Reflux Disease Therapeutics Revenue by Country (2017-2022) & (US$ Million)
Table 62. Middle East and Africa Gastroesophageal Reflux Disease Therapeutics Revenue by Country (2023-2028) & (US$ Million)
Table 63. AstraZeneca Company Details
Table 64. AstraZeneca Business Overview
Table 65. AstraZeneca Gastroesophageal Reflux Disease Therapeutics Product and Services
Table 66. AstraZeneca Gastroesophageal Reflux Disease Therapeutics Revenue in Gastroesophageal Reflux Disease Therapeutics Business (2017-2022) & (US$ Million)
Table 67. AstraZeneca Gastroesophageal Reflux Disease Therapeutics SWOT Analysis
Table 68. AstraZeneca Recent Developments
Table 69. Eisai Company Details
Table 70. Eisai Business Overview
Table 71. Eisai Gastroesophageal Reflux Disease Therapeutics Product and Services
Table 72. Eisai Gastroesophageal Reflux Disease Therapeutics Revenue in Gastroesophageal Reflux Disease Therapeutics Business (2017-2022) & (US$ Million)
Table 73. Eisai Gastroesophageal Reflux Disease Therapeutics SWOT Analysis
Table 74. Eisai Recent Developments
Table 75. Takeda Pharmaceutical Company Details
Table 76. Takeda Pharmaceutical Business Overview
Table 77. Takeda Pharmaceutical Gastroesophageal Reflux Disease Therapeutics Product and Services
Table 78. Takeda Pharmaceutical Gastroesophageal Reflux Disease Therapeutics Revenue in Gastroesophageal Reflux Disease Therapeutics Business (2017-2022) & (US$ Million)
Table 79. Takeda Pharmaceutical Gastroesophageal Reflux Disease Therapeutics SWOT Analysis
Table 80. Takeda Pharmaceutical Recent Developments
Table 81. GlaxoSmithKline Company Details
Table 82. GlaxoSmithKline Business Overview
Table 83. GlaxoSmithKline Gastroesophageal Reflux Disease Therapeutics Product and Services
Table 84. GlaxoSmithKline Gastroesophageal Reflux Disease Therapeutics Revenue in Gastroesophageal Reflux Disease Therapeutics Business (2017-2022) & (US$ Million)
Table 85. GlaxoSmithKline Gastroesophageal Reflux Disease Therapeutics SWOT Analysis
Table 86. GlaxoSmithKline Recent Developments
Table 87. Johnson & Johnson Company Details
Table 88. Johnson & Johnson Business Overview
Table 89. Johnson & Johnson Gastroesophageal Reflux Disease Therapeutics Product and Services
Table 90. Johnson & Johnson Gastroesophageal Reflux Disease Therapeutics Revenue in Gastroesophageal Reflux Disease Therapeutics Business (2017-2022) & (US$ Million)
Table 91. Johnson & Johnson Gastroesophageal Reflux Disease Therapeutics SWOT Analysis
Table 92. Johnson & Johnson Recent Developments
Table 93. Daewoong Pharmaceutical Company Details
Table 94. Daewoong Pharmaceutical Business Overview
Table 95. Daewoong Pharmaceutical Gastroesophageal Reflux Disease Therapeutics Product and Services
Table 96. Daewoong Pharmaceutical Gastroesophageal Reflux Disease Therapeutics Revenue in Gastroesophageal Reflux Disease Therapeutics Business (2017-2022) & (US$ Million)
Table 97. Daewoong Pharmaceutical Gastroesophageal Reflux Disease Therapeutics SWOT Analysis
Table 98. Daewoong Pharmaceutical Recent Developments
Table 99. Ironwood Pharmaceuticals Company Details
Table 100. Ironwood Pharmaceuticals Business Overview
Table 101. Ironwood Pharmaceuticals Gastroesophageal Reflux Disease Therapeutics Product and Services
Table 102. Ironwood Pharmaceuticals Gastroesophageal Reflux Disease Therapeutics Revenue in Gastroesophageal Reflux Disease Therapeutics Business (2017-2022) & (US$ Million)
Table 103. Ironwood Pharmaceuticals Gastroesophageal Reflux Disease Therapeutics SWOT Analysis
Table 104. Ironwood Pharmaceuticals Recent Developments
Table 105. Gastroesophageal Reflux Disease Therapeutics Market Trends
Table 106. Gastroesophageal Reflux Disease Therapeutics Market Drivers
Table 107. Gastroesophageal Reflux Disease Therapeutics Market Challenges
Table 108. Gastroesophageal Reflux Disease Therapeutics Market Restraints
Table 109. Research Programs/Design for This Report
Table 110. Key Data Information from Secondary Sources
Table 111. Key Data Information from Primary Sources
List of FiguresFigure 1. Global Gastroesophageal Reflux Disease Therapeutics Sales Market Share by Type: 2021 VS 2028
Figure 2. Antacids Features
Figure 3. H2 Receptor Blockers Features
Figure 4. Proton Pump Inhibitors (PPIs) Features
Figure 5. Pro-kinetic Agents Features
Figure 6. Others Features
Figure 7. Global Gastroesophageal Reflux Disease Therapeutics Sales Market Share by Application: 2021 VS 2028
Figure 8. Hospital Pharmacy Case Studies
Figure 9. Drug Stores Case Studies
Figure 10. General Stores Case Studies
Figure 11. Supermarkets Case Studies
Figure 12. Gastroesophageal Reflux Disease Therapeutics Report Years Considered
Figure 13. Global Gastroesophageal Reflux Disease Therapeutics Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Gastroesophageal Reflux Disease Therapeutics Market Size 2017-2028 (US$ Million)
Figure 15. Global Gastroesophageal Reflux Disease Therapeutics Market Size Market Share by Region: 2021 VS 2028
Figure 16. Global Gastroesophageal Reflux Disease Therapeutics Revenue Market Share by Region in 2017 VS 2022
Figure 17. Global Top 10 Gastroesophageal Reflux Disease Therapeutics Countries Ranking by Market Size (US$ Million) in 2021
Figure 18. Global Gastroesophageal Reflux Disease Therapeutics Market Share by Players in 2021
Figure 19. Global Top Gastroesophageal Reflux Disease Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastroesophageal Reflux Disease Therapeutics as of 2021)
Figure 20. The Top 10 and 5 Players Market Share by Gastroesophageal Reflux Disease Therapeutics Revenue in 2021
Figure 21. North America Gastroesophageal Reflux Disease Therapeutics Revenue Market Share by Company in 2021
Figure 22. North America Gastroesophageal Reflux Disease Therapeutics Revenue Market Share by Type (2017-2028)
Figure 23. North America Gastroesophageal Reflux Disease Therapeutics Revenue Market Share by Application (2017-2028)
Figure 24. North America Gastroesophageal Reflux Disease Therapeutics Revenue Share by Country (2017-2028)
Figure 25. U.S. Gastroesophageal Reflux Disease Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 26. Canada Gastroesophageal Reflux Disease Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 27. Europe Gastroesophageal Reflux Disease Therapeutics Revenue Market Share by Company in 2021
Figure 28. Europe Gastroesophageal Reflux Disease Therapeutics Revenue Market Share by Type (2017-2028)
Figure 29. Europe Gastroesophageal Reflux Disease Therapeutics Revenue Market Share by Application (2017-2028)
Figure 30. Europe Gastroesophageal Reflux Disease Therapeutics Revenue Share by Country (2017-2028)
Figure 31. Germany Gastroesophageal Reflux Disease Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 32. France Gastroesophageal Reflux Disease Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 33. U.K. Gastroesophageal Reflux Disease Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 34. Italy Gastroesophageal Reflux Disease Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 35. Russia Gastroesophageal Reflux Disease Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 36. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Revenue Market Share by Company in 2021
Figure 37. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Revenue Market Share by Type (2017-2028)
Figure 38. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Revenue Market Share by Application (2017-2028)
Figure 39. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Revenue Share by Region (2017-2028)
Figure 40. China Gastroesophageal Reflux Disease Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 41. Japan Gastroesophageal Reflux Disease Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 42. South Korea Gastroesophageal Reflux Disease Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 43. India Gastroesophageal Reflux Disease Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 44. Australia Gastroesophageal Reflux Disease Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 45. Taiwan Gastroesophageal Reflux Disease Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 46. Indonesia Gastroesophageal Reflux Disease Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 47. Thailand Gastroesophageal Reflux Disease Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 48. Malaysia Gastroesophageal Reflux Disease Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 49. Philippines Gastroesophageal Reflux Disease Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 50. Vietnam Gastroesophageal Reflux Disease Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 51. Latin America Gastroesophageal Reflux Disease Therapeutics Revenue Market Share by Company in 2021
Figure 52. Latin America Gastroesophageal Reflux Disease Therapeutics Revenue Market Share by Type (2017-2028)
Figure 53. Latin America Gastroesophageal Reflux Disease Therapeutics Revenue Market Share by Application (2017-2028)
Figure 54. Latin America Gastroesophageal Reflux Disease Therapeutics Revenue Share by Country (2017-2028)
Figure 55. Mexico Gastroesophageal Reflux Disease Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 56. Brazil Gastroesophageal Reflux Disease Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 57. Argentina Gastroesophageal Reflux Disease Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 58. Middle East and Africa Gastroesophageal Reflux Disease Therapeutics Revenue Market Share by Company in 2021
Figure 59. Middle East and Africa Gastroesophageal Reflux Disease Therapeutics Revenue Market Share by Type (2017-2028)
Figure 60. Middle East and Africa Gastroesophageal Reflux Disease Therapeutics Revenue Market Share by Application (2017-2028)
Figure 61. Middle East and Africa Gastroesophageal Reflux Disease Therapeutics Revenue Share by Country (2017-2028)
Figure 62. Turkey Gastroesophageal Reflux Disease Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 63. Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 64. U.A.E Gastroesophageal Reflux Disease Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 65. AstraZeneca Revenue Growth Rate in Gastroesophageal Reflux Disease Therapeutics Business (2017-2022)
Figure 66. Eisai Revenue Growth Rate in Gastroesophageal Reflux Disease Therapeutics Business (2017-2022)
Figure 67. Takeda Pharmaceutical Revenue Growth Rate in Gastroesophageal Reflux Disease Therapeutics Business (2017-2022)
Figure 68. GlaxoSmithKline Revenue Growth Rate in Gastroesophageal Reflux Disease Therapeutics Business (2017-2022)
Figure 69. Johnson & Johnson Revenue Growth Rate in Gastroesophageal Reflux Disease Therapeutics Business (2017-2022)
Figure 70. Daewoong Pharmaceutical Revenue Growth Rate in Gastroesophageal Reflux Disease Therapeutics Business (2017-2022)
Figure 71. Ironwood Pharmaceuticals Revenue Growth Rate in Gastroesophageal Reflux Disease Therapeutics Business (2017-2022)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed